European Journal of Endocrinology (EUR J ENDOCRINOL)

Publisher: European Federation of Endocrine Societies, BioScientifica

Journal description

The journal publishes original research papers, reviews, short communications and case reports within clinical and experimental endocrinology.

Current impact factor: 3.69

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 3.686
2012 Impact Factor 3.136
2011 Impact Factor 3.423
2010 Impact Factor 3.482
2009 Impact Factor 3.539
2008 Impact Factor 3.791
2007 Impact Factor 3.239
2006 Impact Factor 3.145
2005 Impact Factor 2.962
2004 Impact Factor 3.14
2003 Impact Factor 2.941
2002 Impact Factor 2.56
2001 Impact Factor 2.133
2000 Impact Factor 2.315
1999 Impact Factor 2.421
1998 Impact Factor 2.101
1997 Impact Factor 1.968
1996 Impact Factor 1.695
1995 Impact Factor 1.234

Impact factor over time

Impact factor

Additional details

5-year impact 3.58
Cited half-life 6.30
Immediacy index 0.74
Eigenfactor 0.02
Article influence 1.11
Website European Journal of Endocrinology website
Other titles European journal of endocrinology
ISSN 0804-4643
OCLC 29970781
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details


  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • In any repository
    • Publisher's version/PDF cannot be used
    • Set statement to accompany deposit (see policy)
    • Publisher last contacted on 18/04/2013
  • Classification
    ​ white

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Posttraumatic pituitary hormone deficiency is often suggested. The impact of these predominantly mild and often irreproducible deficiencies on outcome is less clear. The study aim was to describe patient reported outcome in a national a-priori unselected cohort of patients with traumatic brain injury (TBI) in relation to deficiencies identified upon pituitary assessment. We conducted a nationwide population-based cohort study. Participants were Danish patients with a head trauma diagnosis recorded in the Danish Board of Health diagnostic code registry; 439 patients (and 124 healthy controls) underwent assessment of anterior pituitary function 2.5 years (median) after TBI. Questionnaires on health related quality of life (QoL)(SF36, EQ5D, QoLAGHDA) and fatigue (MFI-20) were completed in parallel to pituitary assessment. Patients with TBI had significant detriments in QoL. Impairment (mainly physical scales) related to pituitary deficiency, though only partially confirmed after adjustment for demographic differences. Hypogonadotrophic hypogonadism related to several QoL scores. Increasing impairments were observed with declining total-testosterone (men), but not free-testosterone or any other hormone concentrations. Total-testosterone was not independently related to impaired QoL and fatigue, after adjustment for demographics, and treatment with antidiabetics, opioids, antidepressants and anticonvulsants. Only a very limited relationship between pituitary hormone deficiencies and QoL/fatigue was demonstrated. Due to the dominating influence of concurrent comorbidities, pituitary deficiencies were not independently related to QoL/fatigue. Causality is still to be shown, and whether substitution therapy could be of additional relevance in selected patients needs to be proven.
    European Journal of Endocrinology 03/2015; DOI:10.1530/EJE-14-1069
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unilateral adrenalectomy is the first-line treatment for aldosterone-producing adenomas (APA). Hyperkalemia after adrenalectomy because of contralateral zona glomerulosa insufficiency has been reported. We investigated clinical risk factors to predict postoperative hyperkalemia in patients with APA undergoing adrenalectomy. The study was conducted by retrospective review of medical records from 2000-2012 at Seoul National University Hospital and two other tertiary centers. Data from 124 patients who underwent adrenalectomy were included. Hyperkalemia was defined as serum potassium >5.5 mmol/l. Clinical preoperative risk factors included age, blood pressure, plasma renin activity (PRA), plasma aldosterone concentration (PAC), serum potassium, serum creatinine, glomerular filtration rate (GFR), the mass size on pathology and mineralocorticoid receptor (MR) antagonist use. Thirteen of 124 patients (10.5%) developed postoperative hyperkalemia. The incidences of transient and persistent hyperkalemia were 3.2% and 7.3%, respectively. Preoperative PRA and PAC were not significantly different in postoperative hyperkalemic patients compared with normokalemic patients. Patients with persistent hyperkalemia were older, had a longer duration of hypertension, larger mass size on pathology, and lower GFR (all P <0.05). The incidence of postoperative hyperkalemia was not different between MR antagonist users and non-users. Older age (≥53 years), longer duration of hypertension (≥9.5 years), larger mass size on pathology (≥1.95 cm), and impaired preoperative renal function (GFR <58.2 ml/min) were associated with prolonged postoperative hyperkalemia in patients with APA. MR antagonist use did not prevent postoperative hyperkalemia. .
    European Journal of Endocrinology 03/2015; DOI:10.1530/EJE-15-0074
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Gel filtration chromatography (GFC), the gold standard for macroprolactinaemia (MPRL) diagnosis is slow, costly and labour-intensive. To limit the number of GFC required, we evaluated two screening tests for MPRL: prolactin (PRL) recovery after polyethylene glycol (PEG) precipitation and prolactin concentration ratio, derived from two assays, each having different big-big-prolactin cross-reactivities. In some patients, MPRL is characterised by clinical symptoms which can be associated with an excess of monomeric prolactin. We compared the monomeric prolactin concentration obtained from GFC with the prolactin concentration 1) on a cobas® e 601 analyser and 2) in the supernatant after PEG precipitation. Design and methods: We studied hyperprolactinaemic sera subjected to physician-ordered GFC, between February 2013 and July 2014. We performed PEG precipitation (to evaluate the PRL concentration and rate of recovery in the supernatant) and two prolactin assays: radioimmunoassay (RIA) and electrochemiluminescent assay (ECLIA), on a Roche cobas® e 601 analyser, and calculated the RIA/ECLIA ratio. Results: Among the 222 sera, we were able to diagnose or exclude MPRL in 72.1% of cases, based solely on the ratio and/or recovery. In the remaining cases, GFC was necessary for making a diagnosis. Elevated monomeric PRL was present in 10.9% of macroprolactinaemic sera. In the case of MPRL, both prolactin measurements on the cobas® analyser and in the supernatant weakly correlated to monomeric prolactin values obtained from GFC. Conclusions: The combination of PEG and RIA/ECLIA ratio analysis reduced the number of necessary GFC. However, GFC is essential in MPRL cases to evaluate the monomeric PRL concentration.
    European Journal of Endocrinology 03/2015; DOI:10.1530/EJE-14-1073
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The association between coffee intake and type 2 diabetes may be modulated by common genetic variation. Objective: The purpose of this study was to examine the association between habitual coffee intake and the risk of type 2 diabetes and to determine whether this association varies by genetic polymorphisms related to type 2 diabetes in Korean adults. Design and Methods: A population-based cohort study over a follow-up of 4 years was conducted. A total of 4,077 Korean men and women aged 40-69 years with a normal glucose level at baseline were included. Coffee intake was assessed using a validated food frequency questionnaire and incident type 2 diabetes or pre-diabetes was defined by oral glucose tolerance test or fasting blood glucose test. The genomic DNA samples were genotyped with the Affymetrix Genome-Wide Human SNP Array 5.0 and 9 single nucleotide polymorphisms related to type 2 diabetes in East Asian populations were extracted. Results: A total of 120 cases of type 2 diabetes and 1,128 cases of pre-diabetes were identified. After adjustment for potential confounding factors, we observed an inverse association, but without any clear linear trend, between coffee intake and the combined risk of type 2 diabetes and pre-diabetes. We found that inverse associations between habitual coffee intake and the combined risk of type 2 diabetes and pre-diabetes were limited to those with the T-allele (GT/TT) of rs4402960 in IGF2BP2, those with the G-allele (GG/GC) of rs7754840 in CDKAL1, or those with CC of rs5215 in KCNJ11. Conclusion: We found a lower risk of pre-diabetes and type 2 diabetes combined with coffee intake among individuals with the GT/TT of IGF2BP2 rs4402960, GG/GC of CDKAL1 rs7754840, or CC of KCNJ11 rs5215 which are known to be related to type 2 diabetes in East Asians.
    European Journal of Endocrinology 03/2015; DOI:10.1530/EJE-14-0805
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Neonatal diabetes mellitus (NDM), is a rare form of monogenic diabetes, and usually presents in the first 6 months of life. We aimed to describe the clinical characteristics and molecular genetics of a large Turkish cohort of NDM patients from a single centre and estimate an annual incidence rate of NDM in South-Eastern Anatolian region of Turkey. Design and Methods: NDM patients presenting to Diyarbakir Children State Hospital between 2010 and 2013, and patients under follow up with presumed type 1 diabetes mellitus, with onset before 6 months of age were recruited. Molecular genetic analysis performed. Results: Twenty-two patients(59% males) were diagnosed with NDM(TNDM-5;PNDM-17). Molecular genetic analysis identified a mutation in 20(95%) patients who a mutation analysis was undertaken. In TNDM patients, the genetic cause included chromosome 6q24 abnormalities(n=3), ABCC8(n=1) and homozygous INS(n=1). In PNDM patients, homozygous GCK(n=6), EIF2AK3(n=3), PTF1A(n=3), and INS(n=1) and heterozygous KCNJ11(n=2) mutations were identified. Pancreatic exocrine dysfunction was observed in patients with mutations in the distal PTF1A enhancer. Both patients with a KCNJ11 mutation responded to oral sulfonylurea. A variable phenotype was associated with the homozygous c.-331C>A INS mutation, which was identified in both a PNDM and TNDM patient. The annual incidence of PNDM in South-East Anatolian region of Turkey was 1 in 48,000 live births. Conclusions: Homozygous mutations in GCK, EIF2AK3 and the distal enhancer region of PTF1A were the commonest causes of NDM in our cohort. The high rate of detection a mutation likely reflects the contribution of new genetic techniques (targeted next generation sequencing) and increased consanguinity within our cohort.
    European Journal of Endocrinology 03/2015; DOI:10.1530/EJE-14-0852
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intravenous glucocorticoid (i.v.GC) pulse therapy for Graves' ophthalmopathy (GO) can be associated with acute liver damage (ALD), which was roughly estimated to occur in ∼1% of patients, with an overall mortality of 0.4%. The aim of this study was to evaluate the frequency of ALD after the introduction of a series of exclusion criteria and preventive measures. Retrospective evaluation of all consecutive patients candidate to i.v.GC over a period of 5 years. The study includes 376 GO patients candidate to i.v.GC. Several liver tests were performed before, during, and after i.v.GC. To prevent ALD morbidity and mortality, the following measures were applied: i) exclusion of patients with active viral hepatitis and/or severe liver steatosis; ii) reduction in the GC dose, frequency, and number of pulses; and iii) administration of oral GC after i.v.GC, and also during i.v.GC in patients positive for nonorgan-specific autoantibodies (to prevent autoimmune hepatitis due to immune rebound). ALD was defined as an increase in alanine aminotransferase ≥300 U/l. A total of 353 patients were given i.v.GC and 23 were excluded for various conditions. ALD was detected in 4/376 patients candidate to i.v.GC, resulting in a morbidity of 1.06%. One patient recovered spontaneously and three after additional treatment with oral GC, given to re-establish immune suppression in the suspect of an autoimmune hepatitis. ALD related to i.v.GC is a relatively rare adverse event. Provided an accurate selection of patients and a series of preventive measures are applied, i.v.GC is a safe treatment for the liver. © 2015 European Society of Endocrinology.
    European Journal of Endocrinology 03/2015; 172(3):269-76. DOI:10.1530/EJE-14-0712
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Chromosomal rearrangements of the RET proto-oncogene is one of the most common molecular events in papillary thyroid carcinoma (PTC). However, their pathogenic role and clinical significance are still debated. This study aimed to investigate the prevalence of RET/PTC rearrangement in a cohort of BRAF-wild type PTCs by fluorescence in situ hybridization (FISH) and to search a reliable cut-off level in order to distinguish clonal or non-clonal RET changes. Design: Forty BRAF wild-type PTCs were analyzed by FISH for RET rearrangements. As controls, 6 BRAFV600E mutated PTCs, 13 follicular adenomas (FA) and 10 normal thyroid parenchyma (NTP) were also analyzed. Methods: We performed FISH analysis on formalin-fixed paraffin-embedded (FFPE) tissue using a commercially available RET Break-apart probe. A cut-off level equivalent to 10.2% of aberrant cells was accepted as significant. To validate FISH results, we analyzed the study cohort by qRT-PCR. Results: Split RET signals above the cut-off level were observed in 25% (10/40) of PTCs, harboring a percentage of positive cells ranging from 12% to 50%, and in 1 spontaneous FA (1/13, 7.7%). Overall, the data obtained by FISH matched well with qRT-PCR results. Challenging findings were observed in 5 cases showing a frequency of rearrangement very close to the cut-off. Conclusions: FISH approach represents a powerful tool to estimate the ratio between broken and non-broken RET tumor cells. Establishing a precise FISH cut-off may be useful in the interpretation of the presence of RET rearrangement, primarily when this strategy is used for cytological evaluation or for targeted therapy.
    European Journal of Endocrinology 02/2015; DOI:10.1530/EJE-14-0930
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Pituitary stem cells play a role in the oncogenesis of human adamantinomatous craniopharyngiomas (aCPs). We hypothesized that crosstalk between the Wnt/beta-catenin and Sonic Hedgehog (SHH) pathways, both of which are important in normal pituitary development, would contribute to the pathogenesis of aCPs. Design: To explore the mRNA and protein expression of components of the SHH signaling pathway in aCPs and their relationship with the identification of CTNNB1/beta-catenin mutations and patients outcomes. Patients & Methods: In 18 aCP samples, CTNNB1 was sequenced, and the mRNA expression levels of SHH pathway members (SHH, PTCH1, SMO, GLI1, GLI2, GLI3 and SUFU) and SMO, GLI1, GLI3, SUFU, beta-catenin, and Ki67 proteins were evaluated by qPCR and immunohistochemistry, respectively. Anterior normal pituitaries were used as controls. Associations between molecular findings and clinical data were analyzed. Results: The aCPs presented higher mRNA expression of SHH (+400-fold change [FC]; P<0.01), GLI1 (+102-FC; P<0.001) and GLI3 (+5.1-FC; P<0.01) than normal anterior pituitaries. Longer disease-free survival was associated with low SMO and SUFU mRNA expression (P<0.01 and P=0.02, respectively). CTNNB1/beta-catenin mutations were found in 47% of the samples. aCPs with identified mutations presented with higher mRNA expression of SMO and GLI1 (+4.3-FC; P=0.02 and +10.2-FC; P=0.03, respectively). SMO, GLI1, GLI3, and SUFU staining was found in 85%, 67%, 93%, and 64% of the samples, respectively. Strong GLI1 and GLI3 staining was detected in palisade cells, which also labeled Ki67, a marker of cell proliferation. Conclusions: The upregulation of SHH signaling occurs in aCPs. Thus, activation of Wnt/beta-catenin and SHH pathways, both of which are important in pituitary embryogenesis, appears to contribute to the pathogenesis of aCP.
    European Journal of Endocrinology 02/2015; DOI:10.1530/EJE-14-0934
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Patients with adrenal insufficiency (AI) have impaired health-related quality of life (HRQoL), which is thought to be in part due to unphysiological glucocorticoid replacement therapy. The aim was to compare once-daily hydrocortisone dual-release tablet (modified-release) with conventional hydrocortisone therapy regarding clinical data and HRQoL. Design and Methods: We conducted an open, prospective trial at one endocrine center. 15 of 26 patients with primary AI, 9 of 18 patients with secondary AI, and 6 CAH patients switched to modified-release hydrocortisone therapy by their own decision. We evaluated clinical outcome and disease-specific HRQoL by using AddiQoL questionnaire at baseline and at follow-up (median 202 days (85-498)). Results: Patients on modified-release hydrocortisone (n=30) showed significant decreases in BMI (26.0±0.75 to 25.6±0.71, p for change=0.006) and HbA1c (6.04±0.29 to 5.86±0.28, p for change=0.005), whereas patients remaining on conventional hydrocortisone (n=20) showed no change in these parameters (p for interaction=0.029 and 0.017, respectively). No significant change in AddiQoL score were found in the modified-release hydrocortisone group (83.8 baseline and 84.9 at follow-up; p for change=0.629). In the conventional hydrocortisone group there was a significant decrease in scores (84.0 baseline and 80.9 at follow-up; p for change=0.016), with a between-treatment p for interaction of 0.066. The fatigue subscore of AddiQoL showed the same pattern with a significant decrease (p for change=0.024) in patients on conventional hydrocortisone therapy (p for interaction=0.116). Conclusions: Modified-release hydrocortisone decreases BMI and HbA1c compared to conventional hydrocortisone treatment. In addition, it seems to stabilize HRQoL over time.
    European Journal of Endocrinology 02/2015; DOI:10.1530/EJE-14-1114
  • [Show abstract] [Hide abstract]
    ABSTRACT: Puberty is a remarkable developmental process with the activation of the hypothalamic-pituitary-gonadal axis culminating in reproductive capacity. It is accompanied by cognitive, psychological, emotional and sociocultural changes. There is wide variation in the timing of pubertal onset and this process is affected by genetic and environmental influences. Disrupted puberty (delayed or absent) leading to hypogonadism may be caused by congenital or acquired etiologies and can have significant impact on both physical and psychosocial wellbeing. While adolescence is a time of growing autonomy and independence, it is also a time of vulnerability and thus, the impact of hypogonadism can have lasting effects. This review highlights the various forms of hypogonadism in adolescence and the clinical challenges in differentiating normal variants of puberty from pathological states. Additionally, hormonal treatment, concerns regarding fertility, emotional support, and effective transition to adult care are discussed.
    European Journal of Endocrinology 02/2015; DOI:10.1530/EJE-14-0947
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: 17α-Hydroxylase/17,20-lyase deficiency is a rare cause of 46,XY disordered sex development. Objective: To characterize in vitro and in vivo effects of two novel CYP17A1 gene mutations identified in a patient with a mild phenotype of CYP17A1 deficiency. Subjects and Methods: A 46,XY patient presented with ambiguous genitalia. CYP17A1 deficiency was suspected at 2 months on the basis of steroid analysis performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Mutational analysis of CYP17A1 gene was performed by PCR and Sanger sequencing. To characterize effect of CYP17A1 mutation on 17α-hydroxylase and 17,20-lyase activities in vitro, HEK293 cells were transiently transfected with CYP17A1 expression plasmids, incubated with progesterone or 17OH-pregnenolone and concentrations of 17OH-progesterone or dehydroepiandrosterone were then measured in the cell culture medium by LC-MS/MS. Results: Clinical and hormonal findings in the patient were consistent with partial combined deficiency of 17α-hydroxylase/17,20-lyase. The sequencing of CYP17A1 gene in the patient revealed compound heterozygocity for two novel mutations: c.107delT p.R36fsX107 and p.W121R. In vitro after 6-h culture of transfected HEK293 cells in the presence of 1 μM progesterone 17α-hydroxylase activity of p.W121R mutant was 60.5±16.3%, while 17,20-lyase activity of mutant measured from amount of dehydroepiandrosterone produced in the presence of 1 μM of 17OH-pregnenolone was 15.8±2.6% compared to the wild-type. Conclusions: p.W121R substitution, affecting the first residue in the conserved heme-interacting WXXXR motif of CYP17A1, is associated with partial combined deficiency of 17α-hydroxylase/17,20-lyase.
    European Journal of Endocrinology 02/2015; DOI:10.1530/EJE-14-0834
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Pediatric patients with sellar masses such as craniopharyngioma (CP) or cyst of Rathke's pouch (CRP) frequently suffer disease- and treatment-related sequelae. We analyzed the impact and prognostic relevance of initial hydrocephalus (HY) and hypothalamic involvement (HI) on long-term survival and functional capacity (FC) in children with CP or CRP. Subjects and methods: Using retrospective analysis of patient records, presence of initial HY or HI was assessed in 177 pediatric patients (163 CP, 14 CRP). Twenty-year overall survival (OS) and progression-free survival (PFS), functional capacity, and body mass index (BMI) were analyzed with regard to initial HY, HI, or degree of resection. Results: 105 patients (103/163 CP, 2/14 CRP) presented with initial HY and 96 presented with HI. HY at diagnosis was associated (p=0.000) with papilledema, neurological deficits, and higher BMI at diagnosis and during follow-up. OS, PFS, and FC were not affected by HY at initial diagnosis. HI at diagnosis (96/177) had major negative impact on long-term prognosis. Sellar masses with HI were associated with lower OS (0.84±0.04;p=0.021), lower FC (p=0.003), and higher BMI at diagnosis and last follow-up (p=0.000) when compared with sellar masses without HI (OS: 0.94±0.05). PFS was not affected by HI or degree of resection. Conclusions: Initial HY has no impact on outcome in patients with sellar masses. OS and FC are impaired in survivors presenting with initial HI. PFS is not affected by HY, HI, or degree of resection. Accordingly, gross-total resection is not recommended in sellar masses with initial HI to prevent further hypothalamic damage.
    European Journal of Endocrinology 02/2015; DOI:10.1530/EJE-14-1029
  • [Show abstract] [Hide abstract]
    ABSTRACT: Guideline advice of many Societies on the management of subclinical hypothyroidism in pregnancy suggests treatment when TSH serum levels exceed 2.5 mU/l. Justification of this procedure is based on limited experience, mainly from studies in patients with positive thyroid specific antibodies and higher TSH levels which classically define the condition in the non-pregnant state. Taking into account a lack of clear understanding of the regulation of thyroid hormone transport through the utero-placental unit and in the absence of fetal markers to monitor the adequacy of thyroxine treatment, this review attempts to discuss currently available data and suggests a more cautious approach.
    European Journal of Endocrinology 02/2015; DOI:10.1530/EJE-14-1005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Impairments of muscle function and strength in patients with primary hyperparathyroidism (PHPT) are rarely addressed although decreased muscle function may contribute to increased fracture risk. Objective: We aimed to assess changes in muscle strength, muscle function, postural stability, quality of life (QoL), and well-being during treatment with vitamin D or placebo before and after parathyroidectomy (PTX) in PHPT patients. Design: Randomized placebo controlled trial. Patients: We included 46 PHPT patients, mean age 58 (range 29-77) years and 35 (76%) were women. Interventions: Daily treatment with 70 microgram (2,800 IU) cholecalciferol or placebo for 52 weeks. Treatment was administered 26 weeks prior to PTX and continued for 26 weeks after PTX. Main outcome measures: Changes in QoL and measures of muscle strength and function. Results: Preoperatively, 25-hydroxyvitamin D (25OHD) increased significantly (50 to 94 nmol/L) compared with placebo (57 to 52 nmol/L). We did not measure any beneficial effects of supplementation with vitamin D compared with placebo regarding well-being, QoL, postural stability, muscle strength, or function. In all patients, we measured marked improvements in QoL, well-being (p<0.01), muscle strength in the knee flexion and extension (p<0.001), and muscle function tests (p<0.01) after surgical cure. Postural stability improved during standing with eyes closed (p<0.05), but decreased with eyes open (p<0.05). Conclusions: Patients with PHPT and 25OHD levels around 50 nmol/L did not benefit from vitamin D supplementation concerning muscle strength, muscle function, postural stability, well-being, or quality of life. Independent of preoperative 25OHD levels, PTX improved these parameters.
    European Journal of Endocrinology 02/2015; DOI:10.1530/EJE-14-0940
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperthyroidism is a risk factor for reduced bone mineral density (BMD) and osteoporotic fractures. Vertebral fracture assessment (VFA) by dual-energy X-ray absorptiometry (DXA) is a radiological method of visualization of the spine, which enables patient comfort and reduced radiation exposure. This study was carried out to evaluate BMD and the prevalence of silent vertebral fractures in young men with hyperthyroidism. We conducted a cross-sectional study in a group of Portuguese men aged up to 50 years and matched in hyperthyroidism (n=24) and control (n=24) groups. A group of 48 Portuguese men aged up to 50 years was divided and matched in hyperthyroidism (n=24) and control (n=24) groups. BMD (g/cm(2)) at L1-L4, hip, radius 33%, and whole body as well as the total body masses (kg) were studied by DXA. VFA was used to detect fractures and those were classified by Genant's semiquantitative method. No patient had previously been treated for hyperthyroidism, osteoporosis, or low bone mass. Adequate statistical tests were used. The mean age, height, and total fat mass were similar in both groups (P≥0.05). The total lean body mass and the mean BMD at lumbar spine, hip, and whole body were significantly decreased in the hyperthyroidism group. In this group, there was also a trend for an increased prevalence of reduced BMD/osteoporosis and osteoporotic vertebral fractures. The results obtained using VFA technology (confirmed by X-ray) suggest that the BMD changes in young men with nontreated hyperthyroidism may lead to the development of osteoporosis and vertebral fractures. This supports the pertinence of using VFA in the routine of osteoporosis assessment to detect silent fractures precociously and consider early treatment. © 2015 European Society of Endocrinology.
    European Journal of Endocrinology 02/2015; 172(2):189-194. DOI:10.1530/EJE-14-0602